Amivantamab vs SKB571
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline
Amivantamab
Marketed by Johnson & Johnson and partners
NCT04487080 · Phase 3 · active, not recruiting
This was a randomized phase 3 trial of 1,074 people with an active comparator (osimertinib) and a hard progression-free survival endpoint that was clearly met. The amivantamab plus lazertinib arm was open-label; only the osimertinib and lazertinib-alone arms were blinded, so the main comparison was not blinded.
Next expected readout: December 2026 · NCT06816992 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results. (met)
Result source: NCT04487080
SKB571
Developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07308106 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Amivantamab | SKB571 |
|---|---|---|
| PFS, median | 23.7 vs 16.6vs OsimertinibNCT044870804 other results
| —Not reported |
| OS, median | —Trial running · NCT07100080 | —Not reported |
| ORR | —Trial running · NCT07100080 | —Not reported |
| Duration of response, median | —Trial running · NCT07100080 | —Not reported |
PFS, median
- Amivantamab
- 23.7 vs 16.6vs OsimertinibNCT04487080
4 other results
- 18.5 vs 16.6 NCT04487080
- 11.4 vs 6.7 NCT04538664
- 8.3 vs 4.2 NCT04988295
- 6.3 vs 4.2 NCT04988295
- SKB571
- —Not reported
OS, median
- Amivantamab
- —Trial running · NCT07100080
- SKB571
- —Not reported
ORR
- Amivantamab
- —Trial running · NCT07100080
- SKB571
- —Not reported
Duration of response, median
- Amivantamab
- —Trial running · NCT07100080
- SKB571
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SKB571: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Amivantamab: 3 of 4 rows · SKB571: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Amivantamab |
|---|---|
| Dropout rate | 78.1%Experimental: Arm A (Open-label): a NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 4 more results75%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 81.7% NCT04538664 · Phase 3 · combination 74.5%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 80.2%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | —Experimental: Arm A (Open-label): a NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 4 more results—Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 — NCT04538664 · Phase 3 · combination —Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 —Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 48.7%Experimental: Arm A (Open-label): a NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 4 more results35.2%Experimental: Arm C (Double-blind) NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 37.1% NCT04538664 · Phase 3 · combination 52.1%Main Study: Arm A: Lazertinib + Am NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 32.3%Main Study: Arm C: Amivantamab + C NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | a paronychia 68.4% infusion related reaction 62% rash 61.8% NCT04487080 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 4 more resultsrash 44.6% diarrhoea 31.9% paronychia 28.6% NCT04487080 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 neutropenia 65.8% thrombocytopenia 59.3% infusion related reaction 54% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 infusion related reaction 56.9% neutropenia 56.2% nausea 44.6% NCT04988295 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Amivantamab
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amivantamab's landscape · SKB571's landscape